ArticleEffects of high intravenous doses of dynorphin A(1–13) on tail flick latency and central nervous system histology in rats
-
Add time:09/06/2019 Source:sciencedirect.com
Dynorphin A(1–13) blocks opiate withdrawal in rats without producing dependence, and enhances analgesia in morphine-tolerant animals. Its potential use in humans is therefore of interest. Dynorphin A(1–13) has little toxicity when administered at modest doses IV but has been reported to cause hindlimb paralysis and necrosis of the spinal cord in rats, at the catheter tip, when administered intrathecally. To further evaluate its potential neurotoxicity, we administered dynorphin A(1–13) to rats at very high doses IV. Rats (n = 6–10 per group) received dynorphin A(1–13) as bolus IV doses of 5 mg/kg, or as continuous IV infusions of 40 mg/kg/day for 1 day, with saline controls. The appearance and behavior of all animals was normal. Tail flick latencies remained unchanged (p > 0.5). There were no histologie abnormalities of the spinal cord or brain when examined by light microscopy. Two additional groups received bolus injections of dynorphin A(1–13) 50 or 100 mg/kg IV. Animals receiving 50 mg/kg showed cutaneous flushing, labored respirations, and decreased spontaneous movement, which resolved within 10 min. Histology at 1 week was normal. All six animals receiving 100 mg/kg convulsed and died within minutes. Three animals that received dynorphin A(1–13) 40 mg/kg/day for 7 days had normal behavior and histology. We conclude that the previously observed neurotoxicity of intrathecally administered dynorphin A(1–13) is a local effect that does not occur when dynorphin A(1–13) is administered IV, even at very high doses.
We also recommend Trading Suppliers and Manufacturers of dynorphin A (1-13), Ala(2)-Trp(4)- (cas 104746-05-6). Pls Click Website Link as below: cas 104746-05-6 suppliers
Prev:Dynorphin A (1–13) in the brain suppresses epinephrine-induced ventricular premature complexes and ventricular tachyarrhythmias
Next:Dynorphin A-( 1-13)-Tyr14Leu15-Phe16-Asn17-Gly18-Pro19: a potent and selective κ opioid peptide) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research reportEffect of chronic treatment with morphine, midazolam and both together on dynorphin(1–13) levels in the rat09/09/2019
- ArticleDynorphin a-(1–13)-morphine interactions: Quantitative and qualitative eeg properties differ in morphine-naive vs. Morphine-tolerant rats09/08/2019
- Dynorphin A-( 1-13)-Tyr14Leu15-Phe16-Asn17-Gly18-Pro19: a potent and selective κ opioid peptide09/07/2019
- Dynorphin A (1–13) in the brain suppresses epinephrine-induced ventricular premature complexes and ventricular tachyarrhythmias09/05/2019
- Dynorphin-A-(1–13) antagonizes morphine analgesia in the brain and potentiates morphine analgesia in the spinal cord09/04/2019
- Behavioral effects and in vivo degradation of intraventricularly administered dynorphin-(1-13) and D-Ala2-dynorphin-(1-11) in rats09/03/2019
- Systemic administration of dynorphin A(1–13) markedly inhibits different behavioural responses induced by cocaine in the mouse09/02/2019
- [D-Ala2,(F5)Phe4]-dynorphin1–13-NH2 (DAFPHEDYN): A potent analog of dynorphin 1–1309/01/2019
- Suppression by dynorphin A-(1–13) of the expression of opiate withdrawal and tolerance in mice☆08/31/2019


